Matches 1 - 50 out of 78 1 2 >


Match Document Document Title
US20110015134 Method of treatment for early stage cancer  
This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of...
US20110268820 USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE  
Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally....
US20120232063 2-Aminoindole Compounds And Methods For The Treatment Of Malaria  
The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)—The values and preferred values of the...
US20150080381 METHODS OF TREATING ALOPECIA AND ACNE  
Method of treating alopecia and acne with are disclosed. The compounds fall within described by formula I or II:
US20150231148 TARGETING PRIMARY CILIA TO TREAT GLAUCOMA  
Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.
US20110104121 Female Reproductive Tract and Anal Prophylaxes  
The present invention provides methods for boosting mucosal immunity in the female reproductive tract of pre- and post-menopausal women using a TGF-beta inhibitor, a Selective Estrogen Receptor...
US20150031680 Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof  
The present invention relates to the long-term administration of a selective estrogen receptor modulator (SERM) with a short half-life for the treatment of a variety of estrogen receptor-mediated...
US20110165241 BAZEDOXIFENE FORMULATIONS WITH ANTIOXIDANTS  
This disclosure relates to pharmaceutical compositions comprising bazedoxifene and an antioxidant such as vitamin E, vitamin E TPGS, propyl gallate, citric acid, or BHA/BHT, substantially free of...
US20120135971 ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS  
The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen...
US20150191452 Selective NR2B Antagonists  
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and...
US20110021504 POLYMORPHIC FORM D OF BAZEDOXIFENE ACETATE AND METHODS OF PREPARING SAME  
The present disclosure relates to polymorphic Form D of bazedoxifene acetate, pharmaceutical compositions and methods of treatment using the same, and methods of preparing the same.
US20110028454 DEUTERIUM-ENRICHED BAZEDOXIFENE  
The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20150239838 Compounds for Treatment of Complement Mediated Disorders  
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The...
US20050272717 Treatment of aromatase inhibitor therapy-related osteoporosis  
This invention relates to the use bazedoxifene (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3- methyl-1H-indol-5-ol) in the treatment or inhibition of osteoporosis and osteopenia...
US20140294962 METHOD OF PREPARING POLYMORPHIC PURE FORM A OF BAZEDOXIFENE ACETATE  
The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet...
US20060223791 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof  
A combination product containing at least two active compounds, O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and bazedoxifene or a pharmaceutically acceptable salt thereof...
US20140296213 NEW POLYMORPH  
The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl) benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and...
US20120220558 Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives  
The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which...
US20090054407 Nitrogen-containing heterocyclic compound  
The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—;X represents —C(═O)— or —CHR4— (wherein R4...
US20140228354 Method for Inhibition of Deubiquitinating Activity  
Compounds of the general structure S-1, wherein X and R1-R5 are defined in the specification, are capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs and are useful in...
US20100016290 AMORPHOUS POLYMORPH OF BAZEDOXIFENE ACETATE  
The invention provides a novel polymorphic form C of bazedoxifene acetate, methods of preparing the polymorphic form, and compositions and methods of treatment using the polymorphic form.
US20070142361 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations  
The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as...
US20070049571 Dipiperazinyl ketones and related analogues  
Dipiperazinyl ketones and related analogues are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in...
US20070048374 Bazedoxifene acetate formulations  
The present invention is directed to formulations of bazedoxifene acetate that have reduced polymorph conversion, compositions containing the same, preparations thereof, and uses thereof.
US20120245147 INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH  
Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian...
US20110312945 CRTH2 MODULATORS  
Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus...
US20070010509 Cycloamine ccr5 receptor antagonists  
Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a...
US20110086113 CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (E.G. SERM OR ALKYLATING AGENTS)  
The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in...
US20080119458 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS  
The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the...
US20110065685 NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS  
The present invention provides novel compounds of Formula (I) which are CB2 selective ligands useful for the treatment of pain.
US20110275612 ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM  
Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound...
US20080306047 Use of Aza-Phenylalanine Compounds For Treating Cardiac Arrhythmia  
The present invention relates to the use of certain aza-phenylalanine compounds of formula (I) wherein R1 denotes amino, alkylamino, dialkylamino, amidino, alkylamidino, N-hydroxyamidino, or...
US20070203121 SUBSTITUTED INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS  
The present invention relates to substituted indole compounds of general formula (I), a process for their preparation, medicaments comprising substituted indole compounds as well as the use of...
US20110129542 SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1  
In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I,...
US20070155734 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use  
The invention provides novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions and kits comprising at least one COX-2...
US20140051687 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY  
The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The...
US20110212947 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY  
The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The...
US20100305105 PHENYLSULFOXYOXAZOLE COMPOUND INHIBITORS OF UREA TRANSPORTERS  
Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the...
US20110305661 Carbazole Compounds and Therapeutic Uses of the Compounds  
Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include...
US20070135403 Substituted 2,5-diaminomethyl-1H-pyrrole compounds  
Substituted 2,5-diaminomethyl-1H-pyrroles, a process for the production thereof, pharmaceutical compositions containing them, and the use of these compounds for regulating 5-hydroxytryptamine...
US20060293297 Cyanofluoropyrrolidine derviative  
A cyanofluoropyrrolidine compound of Formula (I) or a pharmaceutically acceptable salt thereof or a hydrate thereof, which is useful as an agent for preventing or treating diseases or conditions...
US20140005174 INDOLE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS  
Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions...
US20080119456 Substituted Thiazoleacetic Acid as Crth2 Ligands  
Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic...
US20070293476 CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS  
The present invention is directed to a method for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective...
US20060189591 Five-membered heterocyclic derivative  
The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the...
US20130217679 Compositions and Methods for Treatment of Neurodegenerative Disease  
Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.
US20110294777 BETA-LACTAMASE INHIBITORS  
Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful...
US20110182888 Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator  
Methods of treating patients with an HDAC inhibitor and a HER-2 inhibitor are provided herein. In some embodiments, a SERM is also administered.
US20080318933 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders  
The present invention relates to novel indole derivatives such as compounds of the formula (I): which possess antagonist potency at the 5-HT6 receptor and the use of such compounds or...
US20100016289 Compounds Useful as Antagonists of CCR2  
The present invention provides compounds of general formula I: (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of...

Matches 1 - 50 out of 78 1 2 >